

Prevention study: A4

This study looks at the ability of a drug (LY2062430 or solanezumab) to delay Alzheimer's disease-related memory loss in older people who have elevated levels of amyloid or beta amyloid proteins in their brain but are not yet displaying symptoms of the disease. Scientists believe these proteins play a key role in development of AD-related memory loss.

We are looking for healthy participants between ages 65-85 who have a study partner who can provide information about the participant's health, attend appointments, and assist with correctly taking study medication. There is no cost to participate and participants will be paid for certain clinical visits. For more information, contact [Kelly Pun](#) at 212-241-8329. Principal Investigator: Mary Sano, PhD; GCO#: 91-0208(0018) and 91-0208(0019); HSM#: 14-00067; ISMMS IRB approved through 03/17/2017.

For those with AD or MCI: SNIFF

This study investigates the safety, tolerability, and effectiveness of an insulin nasal spray administered to people with Alzheimer's disease or mild cognitive impairment. Participants either receive the insulin nasal spray or a placebo nasal spray for 12 months; for the following six months, all participants receive the insulin nasal spray.

We are looking for volunteers who are 55 years of age or older, are diagnosed with mild cognitive impairment or Alzheimer's disease, are fluent in English or Spanish, can attend all study visits, and have a study partner who can also attend all study visits. There is no charge for participation and we serve lunch at some visits. For more information, contact [Michael Kinsella](#) at 212-241-8329. Principal Investigator: Hillel T. Grossman, MD. GCO#: 91-0208(0017); HSM#: 13-00768; ISMMS IRB approved through 10/28/2017.

For those with AD: Grape Seed Extract

The Grape Seed Extract Study is assessing the effect of grape seed extract in people with Alzheimer's disease to determine the safest and most effective dose. Grape seed extract is a natural product that has been shown in laboratory studies to block the formation of brain toxic proteins involved in Alzheimer's disease. Participants will either receive the active compound or a placebo.

We are looking for older adults who are experiencing memory loss that may be due to Alzheimer's disease, who are fluent in either English or Spanish, and who have someone who can act as a study partner. There is no charge to participants. For more information, contact [Florence Lau](#) at 212-241-8329. Principal Investigator: Hillel T. Grossman, MD. ISMMS PPHS approved through 6/30/2017. (GCO #09-0307)

For minority elders with diabetes: Memory and Diabetes Study (MADS)

Studies suggest that diabetes may cause or worsen memory problems in older adults. We are looking to compare memory functioning in older adults with diabetes and those without the disease.

We are recruiting individuals over age 50 from minority backgrounds—because this group is often at highest risk for diabetes and is frequently understudied—who are not experiencing severe memory problems. To learn more, contact [Jorge Ginory-Perez](#) at 718-584-9000 Ext. 1705. Principal Investigator: Corbett Schimming, MD. Study Sponsored by: The National Institute on Aging (NIA) of the National Institutes of Health. ISMMS GCO #84-119 HSM #14-01098; IRB approved through 01/26/2017.

Coming soon:

For those with AD: Biogen study

Very soon the Mount Sinai ADRC will be opening the Biogen study for those who have mild Alzheimer's disease. To learn more about this study, contact Deena Warshaw at 212-659-8845 or email her at Deena.Warshaw@mssm.edu.